(616 Kb) Site

: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials

The researchers analyzed a large group of 616 patients with who were treated with ibrutinib. The goal was to see if the high success rates found in clinical trials were mirrored in everyday medical practice across various hospitals. Key Findings and Statistics (616 KB)

Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC : Despite the high rate of stopping, the

This article, available through PubMed Central (PMC) , provides a comprehensive look at how the drug performs in real-world clinical settings compared to controlled trials. Study Overview: The 616-Patient Cohort available through PubMed Central (PMC)

The study highlighted a few differences between "real-world" patients and those in trials: